N-(5-(3-(N-(4-hydroxyphenyl)sulfamoyl)-4-methoxyphenyl)-4-methylthiazol-2-yl)cyclopentanecarboxamide | 1429624-84-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(5-(3-(N-(4-hydroxyphenyl)sulfamoyl)-4-methoxyphenyl)-4-methylthiazol-2-yl)cyclopentanecarboxamide
• 英文别名: N-[5-[3-[(4-hydroxyphenyl)sulfamoyl]-4-methoxyphenyl]-4-methylthiazol-2-yl]cyclopentanecarboxamide；PT423；AB3480；PI4KIIIbeta-IN-9；N-[5-[3-[(4-hydroxyphenyl)sulfamoyl]-4-methoxyphenyl]-4-methyl-1,3-thiazol-2-yl]cyclopentanecarboxamide
• CAS: 1429624-84-9
• 化学式: C₂₃H₂₅N₃O₅S₂
• 分子量: 487.601
• InChiKey: KAXNDTMKFONXJM-UHFFFAOYSA-N

物化性质

• 密度：
  1.421±0.06 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  154
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-甲氧基-5-(2-氧代丙基)苯磺酰氯 在 tribromure de carboxyethyl-2 triphenylphosphonium 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 1.5h， 生成 N-(5-(3-(N-(4-hydroxyphenyl)sulfamoyl)-4-methoxyphenyl)-4-methylthiazol-2-yl)cyclopentanecarboxamide
  参考文献：
  名称：

  磷脂酰肌醇4激酶IIIβ的有效和选择性抑制剂的设计和结构表征

  摘要：

  III型磷脂酰肌醇4激酶（PI4KIIIβ）是介导膜运输的必不可少的酶，与多种致病过程有关。它是介导RNA病毒复制的关键宿主因子。该酶的有效和特异性抑制剂的设计对于定义其细胞作用至关重要，并可能导致新型抗病毒治疗。我们先前曾报道过PI4K抑制剂PIK93，并且该化合物具有PI4KIIIβ的关键功能。然而，该化合物显示出与I和III类PI3K的高交叉反应性。使用基于结构的药物设计，我们设计了新颖的有效和选择性（比I和III类PI3K高1000倍以上）的PI4KIIIβ抑制剂。这些化合物显示出抗丙型肝炎病毒的抗病毒活性。与最有效的化合物之一结合的PI4KIIIβ的共晶体结构揭示了特异性的分子基础。这项工作对于新型PI4KIIIβ抑制剂的设计至关重要，而PI4KIIIβ抑制剂可能起着重要的抗病毒治疗作用。

  DOI：

  10.1021/acs.jmedchem.5b01311

文献信息

• PI-kinase inhibitors with anti-infective activity
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US10428060B2

  公开（公告）日：2019-10-01

  Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.

  本文提供了用于治疗病原体感染的化合物和方法。在一些实施方案中，抗感染化合物对各种感染性疾病具有广谱活性，其中这些疾病是由含有碱性氨基酸 PIP-2 钳子（BAAPP）结构域的病原体引起的，该结构域与磷脂酰肌醇 4,5-二磷酸（PIP-2）相互作用，介导病原体的复制。还提供了抑制 PI4 激酶的方法和抑制病毒感染的方法。在某些实施方案中，化合物是一种 PI4- 激酶抑制化合物，它是一种 5-芳基噻唑或 5-对位芳基噻唑。主体化合物可与第二种抗感染剂，如干扰素、利比伐林等结合配制或提供给主体。
• PI-kinase Inhibitors with Broad Spectrum Anti-Infective Activity
  申请人：The Regents of the University of California

  公开号：US20150051193A1

  公开（公告）日：2015-02-19

  Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.
• PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20160194314A1

  公开（公告）日：2016-07-07

  Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.
• PI-Kinase Inhibitors with Anti-Infective Activity
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20220017507A1

  公开（公告）日：2022-01-20

  Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-heteroaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.
• P14-Kinase Inhibitors and Methods of Using the Same
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20220153711A1

  公开（公告）日：2022-05-19

  Compounds and methods are provided for inhibiting a PI4-kinase Methods of treating a pathogen infection and methods of treating cancer are also provided. The PI4-kinase inhibitor can be a compound that is a 5-aryl or heteroaryl-thiazole, e.g., as described herein. In certain embodiments, the PI4-kinase inhibitor is a substituted 2-amino-5-phenylthiazole or substituted 2-amino-5-pyridylthiazole compound. In some embodiments, the compounds have broad spectrum anti-infective activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of treating a subject for cancer using a PI4-kinase inhibitor. Aspects of the methods include inhibiting PI4-kinase in a cancer cell to reduce cellular proliferation.